NYSE$USNA
USANA Health Sciences Inc · Q2 2024 earnings
Q2 2024 earnings · · Investor relations
Briefing
USANA's Q2 2024 results were impacted by macroeconomic pressures and lower active customer counts.
USANA Health Sciences reported a decrease in net sales and diluted EPS for the second quarter of 2024 compared to the same period in 2023. The company is updating its fiscal year 2024 net sales and diluted EPS outlook due to these challenges.
- Second quarter net sales were $213 million, down from $238 million in Q2 2023.
- Second quarter diluted EPS was $0.54, compared to $0.89 in Q2 2023.
- The company generated $8 million in operating cash flow and ended the quarter with $332 million in cash and cash equivalents.
- Fiscal year 2024 net sales outlook is updated to $850 million to $880 million, and diluted EPS outlook is updated to $2.40 to $2.55.
Headline financials
Revenue & EPS history
USANA · Revenue · Quarterly
$213M
Forward guidance
The Company is updating its net sales and earnings per share outlook for fiscal year 2024, as follows: Consolidated Net Sales $850 - $880 million, Diluted EPS $2.40 - $2.55.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2024
+2.3%
Avg return
Earnings day
+2.0%
Avg return
5 days after
+1.6%
Avg return
30 days after
58%
37 / 64 earnings
Positive
+39.2%
Q2 2015
Best reaction
-24.1%
Q4 2015
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +1.3% | -9.7% | -7.0% | |
| Q3 2025 | -1.6% | -2.8% | -6.0% | |
| Q2 2025 | +4.1% | +0.8% | +1.5% | |
| Q1 2025 | +4.9% | +13.6% | +21.4% | |
| Q4 2024 | +3.9% | -6.2% | -13.1% | |
| Q3 2024 | +4.4% | +5.0% | +12.3% | |
| Q2 2024 | -3.7% | -7.7% | -14.6% | |
| Q1 2024 | +6.0% | +6.0% | +8.7% | |
| Q4 2023 | +7.1% | +9.6% | +4.6% | |
| Q3 2023 | -16.7% | -17.7% | -13.8% | |
| Q2 2023 | +6.5% | +2.1% | -0.3% | |
| Q1 2023 | +4.9% | +2.5% | -4.4% | |
| Q4 2022 | +4.7% | +4.0% | +2.4% | |
| Q3 2022 | -0.2% | -3.0% | -6.5% | |
| Q2 2022 | +1.1% | +1.4% | -0.5% | |
| Q1 2022 | -3.6% | -2.6% | -10.4% | |
| Q4 2021 | -8.4% | -5.2% | -10.1% | |
| Q3 2021 | -8.0% | -3.4% | +1.3% | |
| Q2 2021 | -2.3% | -6.8% | -6.9% | |
| Q1 2021 | -7.7% | -6.4% | +9.4% | |
| Q4 2020 | +15.7% | +6.3% | +16.4% | |
| Q3 2020 | +5.1% | +10.7% | -3.5% | |
| Q2 2020 | -6.4% | -12.4% | -8.8% | |
| Q1 2020 | +17.5% | +25.2% | +23.8% | |
| Q4 2019 | +25.3% | +28.1% | +15.7% | |
| Q3 2019 | +11.5% | +4.8% | +1.8% | |
| Q2 2019 | +0.3% | +6.1% | +5.7% | |
| Q1 2019 | +9.4% | +2.2% | -12.9% | |
| Q4 2018 | -11.4% | -6.5% | -18.1% | |
| Q3 2018 | +3.5% | +2.7% | +13.0% | |
| Q2 2018 | +23.9% | +18.9% | +19.0% | |
| Q1 2018 | +11.6% | +10.3% | +22.2% | |
| Q4 2017 | +5.6% | +7.0% | +14.4% | |
| Q3 2017 | +12.5% | +9.7% | +10.1% | |
| Q2 2017 | -10.0% | -11.2% | -7.5% | |
| Q1 2017 | +6.5% | +13.4% | +16.4% | |
| Q4 2016 | -11.6% | -8.9% | -8.9% | |
| Q3 2016 | -8.2% | -11.5% | -13.6% | |
| Q2 2016 | +11.6% | +8.2% | +8.4% | |
| Q1 2016 | +6.2% | — | — | |
| Q4 2015 | -24.1% | — | — | |
| Q3 2015 | -11.6% | — | — | |
| Q2 2015 | +39.2% | — | — | |
| Q1 2015 | +19.2% | — | — | |
| Q4 2014 | -6.6% | — | — | |
| Q3 2014 | +26.5% | — | — | |
| Q2 2014 | -7.8% | — | — | |
| Q1 2014 | -15.2% | — | — | |
| Q4 2013 | +18.8% | — | — | |
| Q3 2013 | -9.6% | — | — | |
| Q2 2013 | -13.3% | — | — | |
| Q1 2013 | +8.1% | — | — | |
| Q4 2012 | +5.8% | — | — | |
| Q3 2012 | +1.7% | — | — | |
| Q2 2012 | +5.4% | — | — | |
| Q1 2012 | +2.0% | — | — | |
| Q4 2010 | -4.2% | — | — | |
| Q4 2011 | -4.2% | — | — | |
| Q3 2011 | -5.4% | — | — | |
| Q2 2011 | -0.3% | — | — | |
| Q1 2011 | -0.3% | — | — | |
| Q3 2010 | -2.0% | — | — | |
| Q2 2010 | +4.3% | — | — | |
| Q1 2010 | +4.0% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro